Medidata Presents Findings on Analyses of HER2-Negative Patients at the San Antonio Breast Cancer Symposium
Medidata AI recently presented a research poster, “Pooled Clinical Trial Data Analyses Comparing the Biology of HER2-low vs HER2-0 Breast Cancer in Patients with Metastatic Breast Cancer Following Treatment with Standard Single Agent Chemotherapy”, at the San Antonio Breast Cancer Symposium.
This study aimed to further existing research about potential differences in the biology of metastatic breast cancer in women with HER2 negative disease according to the HER2-low vs.HER2-0 subtype. The team studied anonymized patient-level clinical trial data from the Medidata Enterprise Data Store (MEDS) to compare demographic and clinicopathologic features of patients according to HER2 negative subtype. They also evaluated for differences in patients’ overall survival and progression-free survival according to these subtypes.
Ultimately, researchers found that after analyzing pooled historical clinical trial data of women with metastatic HER-2 negative breast cancer, there were no clinically significant or prognostic differences between HER2-negative subgroups (HER2-low vs HER2-0).
This work was conducted by researchers at Medidata and Dana-Farber Cancer Institute: Elizabeth B. Lamont, MD, MS1; Emily Stein, MPH1; Paolo Tarantino, MD2; Sara M Tolaney, MD, MPH2; Corinne Ahlberg1; Krishna Chinnathambu1; Jiezhi Qi1; Kala Tummagunta1; Jackie Bilan1; Ruthanna Davi, PhD1; and Lisa Ensign, PhD1
1Medidata AI, Medidata , a Dassault Systèmes company, New York, NY; 2Dana-Farber Cancer Institute, Boston, MA